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Abstract
Background: The role of excessive adiposity or its metabolic consequences in persistent HPV infection among
general adult women remains unknown.
Methods: Using data from the National Health and Nutrition Examination Survey (NHANES) in 2003–2010, we
compared adult women’s likelihood for any- or high-risk (HR) type HPV infection by degrees of excessive adiposity
and metabolic health status.
Results: Any-type (41.1 % vs. 44.9 %, P = 0.045) or HR-type HPV prevalence (21.9 % vs. 25.4 %, P = 0.055) was
comparable in women aged 20–59 years with or without central obesity. After adjusting for age, socioeconomic
indicators, and lifetime sexual risks, centrally-obese women barely showed a different likelihood for any-type
(aPR [adjusted prevalence ratio] = 0.91, P = 0.03) or HR-HPV infection (aPR = 0.92, P = 0.279). However, obesity
(aPR = 0.76, P = 0.017) or centrally-obesity (aPR = 0.72, P = 0.003) was negatively correlated with HR-HPV infection
in women reporting an early sex debut (<16 years; P for interaction <0.05). In the fasting subpopulation, obesity
(aPR = 0.77, P = 0.016) or metabolically unhealthy obesity (aPR = 0.69, P = 0.018) was significantly correlated with
a 23 % or 31 % reduced prevalence of HR-HPV infection.
Discussion: In contrary to findings for the general population, HR-HPV prevalence was decreased in a subgroup
of women with obesity or central obesity. Possible explanations for such heterogeneity included less risky sexual
behaviors, an altered immune milieu that promoted viral clearance, and increased access to healthcare
resources due to other obesity-related co-morbidities in this subpopulation.
Conclusions: Obesity or central obesity was not significantly associated with prevalent any-type or HR-type HPV
infection among adult women in general. However, in certain subpopulations, excessive adiposity or its relevant
metabolic dysfunction was negatively associated with HR-HPV infection.
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Background
Globally, cervical cancer has ranked the fourth most com-
mon cancer in women and is responsible for 7.5 % of all
cancer mortality for females in 2012 [1]. While most genital
human papillomavirus (HPV) infections are believed to be
transient, [2] for a small at-risk subpopulation, high risk
(HR) or oncogenic type HPV infections can persist and
eventually lead to carcinogenesis at the cervix, anus, oro-
pharynx and other anatomical sites 10–20 years later [1, 3].
Despite continuous epidemiological and clinical research
efforts, host factors for viral clearance or persistence re-
main largely unknown [2]. Lessons learned from immuno-
compromised women, such as those living with human
immunodeficiency virus (HIV), have suggested that host
immunity may play a key role in the clearance or
reactivation of HPV [4, 5].
Not only healthcare-associated infections, such as
surgical site infection, or aspiration pneumonia among
hospitalized patients, [6] an accumulating body of evidence
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has suggested that obesity may predispose individuals to an
increased risk for acute and chronic community-acquired
infections, such as H1N1 influenza virus, [7] herpes sim-
plex virus type 1 (HSV-1) [8] or HPV. [9] Comparing
healthy obese (BMI ≥ 25) with lean (BMI < 25) subjects,
Nieman and colleagues found that obesity was associated
with differences in numbers and chemotactic responses in
subsets of immune cells [10]. Despite this growing body of
evidence showing that a pro-inflammatory state is often
associated with excess adiposity and its metabolic conse-
quences, [11] it remains unclear whether women of exces-
sive adiposity have an altered immune status affecting their
likelihood for HPV persistence.
Previously, we and other colleagues have shown that
obesity or central obesity did not predict the incidence
or regression of HPV DNA detection among a cohort of
U.S. perimenopausal women (aged 35–60) over a median
follow-up period of 18 months [12]. As BMI may not
optimally reflect an individual’s visceral adiposity, [13]
studies have suggested alternative indices, such as waist
circumference (WC), [14] waist-to-height ratio (WHtR),
[15] or waist-to-hip ratio (WHR) [16] to better correlate
with the dysmetabolic state or the degree of low grade
inflammation. Our early cohort study did not address
the potential health effects of excess adiposity on HPV
infection among adult women in general. Nor did it
identify any subgroups of women who may have differ-
ential risks for persistent HPV infections.
Recently, metabolic health has gained an increasing
attention to its potential mediating role in cardiovascular
diseases [17] and cancers [18]. Yet, few studies have
specifically investigated on metabolic health in obesity-
related infection risks. The previous prospective study
did not specifically examine the role of women’s meta-
bolic health in HPV infection due to the lack of relevant
measurements [12]. Assuming that HPV prevalence par-
allels women’s risk for chronic, persistent HPV infection
at the population level, [19] we aimed to compare HPV
prevalence between women with and without excessive
adiposity, as determined by a large waist (>88 cm, cen-
tral obesity) or by BMI (≥30 Kg/m2), using data from the
continuous National Health and Nutrition Exam Survey
(NHANES) in 2003–2010. Also, we sought to explore
whether women’s risk for persistent HPV infection
differed by metabolic health status in the fasting sub-
group. In particular, we attempted to identify subpopula-
tions of women with susceptibility or resistance to HPV
persistence if applicable.
Methods
Study design and population
The National Center for Health Statistics (NCHS) has
obtained ethical approval from NCHS Research Ethics
Review Board before each survey cycle [20]. Details
regarding the survey design, contents of questionnaire,
and data collection of the continuous NHANES program
can be accessed online [21]. In brief, adults aged 20 or
older were interviewed during a household visit and
examined at the mobile examination center (MEC)
where specimens were also collected. Comprehensive
demographic, socioeconomic and behavioral information
were documented at the interview. For the subgroup
analysis, we included women whose anthropometric
measures and fasting laboratory findings were available
for characterizing a subject’s metabolic health status. Only
women attending the morning session and who had
fasted ≥ 8 h were included for the subgroup analysis. Self-
reported pregnancy status at the time of the exam was
further confirmed by results of urine pregnancy test. As
the current study involved secondary analysis of pub-
licly available, de-identified data, the institutional review
boards of the Chang Gung Memorial Hospital at Linkou
has reviewed the analytic plan and waived the consen-
ting requirement (No.102–0389B).
Data collection
In 2003–2004, HPV DNA extracted from women’s self-
collected vaginal swabs were tested for the presence of
37 HPV types using the Roche prototype line blot assay,
which was replaced by the Roche Linear Array (LA) kit
since 2005 [21]. Residual DNA extracts from NHANES
2003–2004 were thus retyped using the LA kit to allow
for data comparison and trend analysis [22]. The current
analysis was based on the LA genotyping results, and a
swab result was excluded when the swab was negative
for human β-globin. Any-type HPV positivity was
defined by at least one positive out of 37 genotypes
whereas oncogenic type positivity was determined by
positive findings in the following 14 types: 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 [21].
Definitions for excess adiposity
Obesity was defined based on WHO classification (BMI ≥
30 kg/m2) [23] whereas central obesity was determined
based on the National Cholesterol Education Program’s
Adult Treatment Panel III report (ATP III, >88 cm for
women) [24]. A cut-off value of 0.6 was employed for
using waist-to-height ratio (WHtR) to characterize women
of a large waist [15].
Definitions for metabolic health
For the fasting subgroup, the ATP III criteria was also
adopted for defining metabolic syndrome (MetS) according
to the presence of the following metabolic risk factors, in-
cluding central obesity; the diagnosis of or the current use
of prescription drugs for hypertension (blood pressure ≥130/
85 mmHg) or diabetes (fasting glucose ≥ 100 mg/dL); a dys-
lipidemic profile (triglyceride [TG] ≥ 150 mg/dL or high-
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density cholesterol [HDL] <50 mg/dL for women). A previ-
ously published definition was applied to defining individual
metabolic health status as healthy (none or one of metabolic
risk factors) or unhealthy (two or more metabolic risk
factors) such that participants were further grouped into
one of the four metabolic-obese phenotypes based on their
obesity and metabolic health status- metabolically healthy
and nonobese (MHNO), metabolically healthy but obese
(MHO), metabolically unhealthy nonobese (MUNO) and
metabolically unhealthy obese (MUO) [25]. Different criteria
for central obesity (WHO recommendation: 80 cm for
Europid or Non-Hispanic White women) [26], hypertriglyc-
eridemia (177 mg/dL or 2.0 mmol/L) and for MetS (The
International Diabetes Federation [IDF] consensus) [27]
were considered in separate sensitivity analyses.
Other covariates
A participant’s race or ethnicity identity was grouped into
one of the following categories: non-Hispanic White, non-
Hispanic Black, and others including Mexican American.
Women were also classified as being married, single, or
living with a partner according to self-reported relation-
ship at the time of the interview. The question about
health insurance coverage did not discern about public or
private insurance providers. Information regarding other
cardio-metabolic risk factors was based on self-report, in-
cluding the medical history of hypertension and diabetes.
To avoid surveillance bias, we did not consider a partici-
pant’s average blood pressure measurement (systolic
>140 mg or diastolic >85 mg) or plasma levels of fasting
glucose (>100 mg/dL, if available) at the time of the survey
but only her self-reported clinical diagnosis and prescribed
medication usage to infer her medical conditions.
Behavioral risk factors included: lifetime smoking ≥100
pieces, alcohol use >12 drinks in the previous 12 months;
sexual exposure history as categorized by numbers of cu-
mulative and recent sexual partners: low (lifetime sexual
partners <5), moderate (lifetime sexual partners ≥ 5 and
recent sexual partners <5 over the previous 12 months),
and high risk (both lifetime and recent sex partners ≥ 5);
self-reported use of condom (not always versus always) in
the previous 30 days (in 2003–2004) or in the previous
12 months (in 2005–2010); current use of oral contracep-
tive use or not.
Statistical analysis
Applying sampling weights to account for the multi-
level, stratified, probability sampling and non-response
rates in the NHANES, [22] we calculated population-
based prevalence estimates of any-type HPV infection
for the overall study populations and by age groups, race
or ethnicity, survey years, and other individual character-
istics. We compared prevalence of any-type and HR-type
HPV by nominal covariates using design-based Chi-
squared statistics. Due to the high prevalence of HPV in-
fection, we applied Poisson regression models to compare
adjusted prevalence ratios [28]. We also confirmed model
results with those obtained by use of negative binomial
models to ensure the variance assumption was not vio-
lated in Poisson models. In addition to stratified analysis,
we further evaluated the following explanatory variables
for a potential modulating effect on the adiposity-HPV
association: age (<35 vs. 35 years or older); ethnicity
(non-Hispanic white vs. non-Hispanic black vs. others);
education (high school or fewer vs. college or higher);
age at sexual debut (<16 vs. 16 years or older); high cu-
mulative sexual exposure (<5 vs. 5 lifetime sex partners
or more). All analysis was performed in Stata 13 with a
two-tailed significance level of 0.05 [29].
Results
In 2003–2010, 16,729 adults aged 20 years or older com-
pleted measurements of blood pressure, body weight
and height, and waist circumference (Additional file 1:
Figure S1). Women aged 20–59 years were asked to pro-
vide a vaginal swab, from which the LA genotyping
results for HPV DNA testing were available from 5372
individuals. Among 4172 women who were included in
the primary analysis (Additional file 1: Figure S1),
there was no significant temporal change in any-type
or HR-type HPV prevalence across the eight survey
years (P = 0.143 and P = 0.853, respectively, Table 1).
Excess adiposity and HPV infection
Women with central obesity had a slightly reduced
(any-type: 41.1 % vs. 44.9 %, P = 0.045) or comparable
(HR-type: 21.9 % vs. 25.4 %, P = 0.055) HPV preva-
lence. BMI-based adiposity measures, such as obesity
(P = 0.451 for any-HPV; P = 0.191 for HR-HPV) and
BMI categories (P = 0.36 for any-HPV; P = 0.345 for
HR-HPV), were not associated with HPV prevalence
(Table 1). Except for a diabetic history and current use of
oral contraceptives, women who were positive for any-
type and HR-type HPV DNA testing were likely to be
young (Fig. 1) and shared common socio-demographic
and behavioral risk factors (all P-values <0.001, Table 1).
After adjusting for age, socio-economic factors and risky
behaviors, centrally-obese women had a 9 % reduced
prevalence for any-HPV (aPR = 0.91, 95 % confidence
interval [CI] = 0.84–0.99; P = 0.03) but not for HR-HPV
(aPR = 0.92, 95 % CI = 0.79-1.07; P = 0.279) infection as
compared to women of normal WC (≤88 cm). Meanwhile,
neither obesity nor a high waist-to-height ratio (>0.6)
showed statistical associations with any-type or HR-type
HPV infections (Table 2).
In women who reported an early sex debut (<16 years),
we noted that, obese women had 24 % lower likelihood
for HR-HPV infection (aPR = 0.76, P = 0.017) than their
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counterparts whereas women who had sex debut at age
16 or later had a comparably low HR-HPV prevalence
regardless of their BMI (P-value for interaction = 0.006,
Table 3). Likewise, we also observed such differential effect
on the association between central obesity and HR-HPV
(P-value for interaction = 0.019, Table 3) by early sex debut.
Despite of an overall null association between obesity or
central obesity with any-type HPV infection, centrally-
obese women were at a 13 % reduced probability for any-
type HPV infection as compared to women with a normal
WC (aPR = 0.87, P = 0.028) only in the non-Hispanic White
subpopulation; though such racial differences were not
statistically significant (Additional file 1: Figure S2).
Metabolic health and HPV infection
Among 1987 fasting women who were included for the
subgroup analysis, prevalence of any-type (42.3 %) or
oncogenic (22.9 %) HPV infection was comparable to
that of the primary study population (Table 1). Despite
that women of excess adiposity were similarly distrib-
uted in the fasting subgroup (Additional file 1: Table S1)
as compared to the primary study population, fasting
women who were positive for oncogenic HPV were
more likely to be in the lean or normal-waist group (all
Table 1 Weighted prevalence of any-type and high-risk type HPV
by selected characteristics of women aged 20–59 (N = 4172) in
NHANES 2003–2010
Participant characteristics Any-type HPV High-risk type
HPV
% p-valuea % p-valuea
Overall 42.6 % 23.3 %
Survey year
2003–2004 47.2 % 0.143 23.5 % 0.853
2005–2006 40.3 % 24.7 %
2007–2007 41.5 % 22.7 %
2009–2010 42.4 % 22.7 %
Adiposity metrics
Central obesity: waist > 88 cm 41.1 % 0.045 21.9 % 0.055
waist < = 88 cm 44.9 % 25.4 %
Obesity: BMI > = 30 Kg/m2 41.7 % 0.451 22.0 % 0.191
BMI < 30 Kg/m2 43.2 % 24.0 %
Waist-to-height ratio: ≥ 0.6 42.5 % 0.884 22.2 % 0.209
< 0.6 42.7 % 24.0 %
BMI, Kg/m2
18.5–25 42.4 % 0.360 23.9 % 0.345
25–30 44.2 % 24.3 %
30–35 39.7 % 20.3 %
≥ 35 43.6 % 23.6 %
Socio-demographics
Age, years
20–34 51.8 % <0.001 33.9 % <0.001
35–49 40.1 % 20.2 %
50–59 35.0 % 14.8 %
Race/ethnicity
Non-Hispanic White 39.6 % <0.001 21.8 % <0.001
Non-Hispanic Black 59.9 % 33.0 %
Mexican American/others 43.3 % 23.1 %
Education≥ College degree 33.0 % <0.001 15.6 % <0.001
High school or less 46.4 % 26.3 %
Marital status
Married 30.0 % <0.001 13.9 % <0.001
Single 59.2 % 35.7 %
Living with a partner 59.0 % 35.5 %
Health insurance coverageb: yes 40.0 % <0.001 21.6 % <0.001
no 54.2 % 30.7 %
Behavioral risks
Hypertension historyc: yes 41.1 % 0.419 20.2 % 0.021
no 43.0 % 24.2 %
Table 1 Weighted prevalence of any-type and high-risk type HPV
by selected characteristics of women aged 20–59 (N = 4172) in
NHANES 2003–2010 (Continued)
Diabetes historyd: yes 46.5 % 0.285 19.0 % 0.209
no 42.5 % 23.7 %
Lifetime smoking: ≥ 100 cigarettes 49.4 % <0.001 26.4 % 0.004
< 100 cigarettes 37.3 % 20.9 %
Last 12 months had
≥ 12 alcohol drinkse
44.4 % 0.001 25.0 % <0.001
< 12 alcohol drinks 37.7 % 18.7 %
Age at sex debut > =16 39.3 % <0.001 21.6 % <0.001
<16 52.8 % 28.6 %
Number of lifetime sex partners
> =5f
54.5 % <0.001 31.3 % <0.001
< 5 28.2 % 14.1 %
Condom use: not alwaysg 50.6 % <0.001 32.0 % <0.001
Always 37.7 % 19.4 %
Use of birth control pills: currentlyh 45.7 % 0.173 29.2 % 0.003
Not currently 42.3 % 22.5 %
BMI body mass index, SE standard error
aP-value for survey-based Chi-squared test
bSix women had a missing value
cEleven women had a missing value
dTwenty women had a missing value
eThree women had a missing value
fForty women had a missing value
gQuestion was asked regarding the previous 30 day alcohol use in 2003–2004
but the previous 12 months in 2005–2010; 652 women did not answer
this question
hFourteen women had a missing value
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P-values <0.05) in univariate analysis. Additionally,
57.9 % of fasting women were metabolically healthy with
a BMI at the normal range, 7.7 % were metabolically un-
healthy non-obese (MUNO), 16.0 % were metabolically
healthy yet obese (MHO); 18.5 % met the ATP III cri-
teria for metabolic syndrome and were obese. Prevalence
of any-type HPV for women in the four metabolic
health-obese groups was alike (P = 0.372) whereas that
of oncogenic HPV was substantially lower in obese
women with MetS (14.9 %, P = 0.005). Otherwise, distri-
butions of fasting women with positive HPV DNA for
any type or oncogenic types were also similar among dif-
ferent groups as compared to the primary population
(Additional file 1: Table S2).
Results of multivariable Poisson regression showed
that, in general, neither excessive adiposity nor meta-
bolic health status was correlated with any-type HPV in-
fection (Table 4). Nevertheless, obese women overall had
a 23 % reduction in HR-HPV infection as compared to
that of normal-BMI individuals (aPR = 0.77, P = 0.016;
Table 4). Metabolically unhealthy obese women also had
a more than 30 % lower probability for HR-HPV infec-
tion than women with normal BMI and metabolic health
status did (aPR = 0.69, P = 0.018; Table 4). We did not
identify any significant host characteristics that moder-
ated fasting women’s likelihood for HPV infection in
further subgroup analysis.
Discussion
The current study extended a previous investigation on the
obesity-HPV association from a specific age group (aged
35–60) [12] to adult women in general (aged 20–59). Over-
all, we found a null or weak association between obesity or
central obesity and HPV infection in this nationally-
representative adult female population. However, sub-
group analysis showed that obese or centrally-obese
women had a significantly reduced HR-HPV infection
among those who reported an early sex debut
Fig. 1 Age-specific prevalence of central obesity, obesity, any-type HPV and high risk (HR) type HPV in adult women enrolled in NHANES 2003–2010.
Weighted prevalence estimates for women with central obesity, obesity, positive HPV DNA testing for any type or high-risk (or, oncogenic) types were
displayed on the same graph. These single-year estimates for each age group were averages across the four survey cycles, despite of some variations,
showing a generally increasing (for excessive adiposity) or decreasing trend (for HPV infection) towards older age. While these age-associated variations
in central obesity and obesity parallel with each other, any-type and HR-type HPV prevalence became discordant around ages 40–44 years, at which
time there was an apparent dip in HR-HPV prevalence
Table 2 Results of multivariable Poisson regression on any- or high risk-type HPV prevalence by central obesity or obesity, adult
women aged 20–59 (N = 4126a) in NHANES 2003–2010
Any-HPV HR-HPV
95 % CI 95 % CI
aPRb LL UL p-value aPRb LL UL p-value
WHtR > 0.6 0.98 0.90 1.07 0.671 0.95 0.84 1.08 0.437
Obesity (BMI≥ 30 kg/m2) 0.94 0.86 1.02 0.109 0.90 0.79 1.02 0.097
Central obesity (waist >88 cm) 0.91 0.84 0.99 0.030 0.92 0.79 1.07 0.279
BMI body mass index. CI confidence interval, aPR adjusted prevalence ratio, LL lower limit, UL upper limit, WHtR Waist-to-height ratio
aForty out of 4172 women had missing formation about number of lifetime partners; six were missing information about health insurance coverage
bAdjusting for survey cycle, age, race/ethnicity, college degree or not, marital status, health insurance coverage or not, and lifetime sexual exposure
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(<16 years) or those included in the fasting subpopu-
lation. We proposed three potential mechanisms for
these observed negative correlations.
First, despite the early sex debut, adult women with
excessive adiposity might have a lower HPV burden than
women with normal BMI or WC. Early studies on adoles-
cents have consistently linked early sex debut to an
increased risk for sexually transmitted infections (STI), in-
cluding HPV infection [30, 31]. The heightened STI risks
were reportedly mediated by concomitant risky behaviors
such as frequency of sex, irregular use of condom, alcohol
use and a smoking habit [31]. In our analysis, additional
adjustment for behavioral factors, such as condom use,
drinking history in the last 12 months and cumulative
smoking exposure did not change our results. It was pos-
sible that obese or centrally obese women who initiated
sex activities early may have had a less risky behavioral
profile, either in adolescence or early adulthood, resulting
in fewer new acquisitions or re-infections overall.
Secondly, we hypothesized that the altered host immune
responses in obese or centrally-obese women may have
facilitated viral clearance (in adolescence) or suppress viral
reactivation from latent, persistent HPV infections (in
mid- or late adulthood). Higher concentrations of several
cytokines, including tumor necrosis factor (TNF)-α, inter-
leukin (IL)-6 and others, were found in immature cervical
epithelium than those in mature, squamous cervical epi-
thelium [32]. Whether such elevation in innate immune
responses translates into effective defenses against viral
pathogens in adolescents remains unknown. Women who
had been obese (or centrally-obese) since adolescence
could have outperformed their peers in controlling early
HPV infections due to their pro-inflammation milieu.
Besides, for adult women with excessive adiposity, their
hyper-activated adaptive immunity [33] might have held
latent viruses in check, reducing chances of ageing-
associated viral reactivation as compared to women of
normal BMI or WC [34].
Table 3 Results of stratified analysis by age first sex debut suggesting differential modulating effects the associations between
excessive adiposity and risks for high-risk type HPV infection among adult women in NHANES 2003–2010 (N = 4124a)
HR-HPV Reported age at first sex
<16 years (n = 1112) > = 16 years (n = 3012)
95 % CI 95 % CI
aPR LL UL p-value aPR LL UL p-value
Obesity vs. BMI < 30 kg/m2* 0.76 0.60 0.95 0.017 0.98 0.85 1.13 0.744
Central obesity vs. WC≤ 88 cm** 0.72 0.59 0.89 0.003 1.03 0.86 1.24 0.726
aPR adjusted prevalence ratio, BMI body mass index, CI confidence interval, HR high risk type, LL lower limit, NHANES National Health and Nutrition Examination
Survey, UL upper limit, WC waist circumference
*P for interaction = 0.006
**P for interaction = 0.019
aForty out of 4172 women had missing formation about number of lifetime partners; six were missing information about health insurance coverage; two did not
report age at sex debut
Table 4 Results of multivariable Poisson regression on any- or high risk-type HPV prevalence by adiposity and metabolic health status,






LL UL p-value LL UL p-value
WHtR > 0.6 0.97 0.86 1.08 0.542 0.82 0.66 1.02 0.074
Obesity (BMI≥ 30 kg/m2) 0.96 0.85 1.09 0.534 0.77 0.62 0.95 0.016
Central obesity (WC >88 cm) 0.96 0.86 1.08 0.502 0.89 0.72 1.09 0.254
MetS 0.98 0.84 1.14 0.760 0.85 0.68 1.08 0.176
Metabolic health and obesity
Normal 1.00 1.00
MUNO 1.06 0.83 1.36 0.625 1.19 0.88 1.62 0.263
MHO 1.00 0.84 1.19 0.971 0.86 0.68 1.09 0.204
MetS & obese 0.94 0.80 1.11 0.478 0.69 0.51 0.94 0.018
aPR adjusted prevalence ratio, BMI body mass index, CI confidence interval, LL lower limit, MetS metabolic syndrome by ATP III criteria, MHO metabolically healthy
and obese, MUNO metabolically unhealthy and non-obese, UL upper limit, WC waist circumference, WHtR waist-to-height ratio
aFifteen out of 1987 women had missing formation about either number of lifetime partners or health insurance coverage
bAdjusting for survey cycle, age, race/ethnicity, college degree or not, marital status, health insurance coverage or not, and lifetime sexual exposure
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Lastly, obese individuals may have paid more visits to
healthcare providers because of their cardio-metabolic co-
morbidities, such as hypertension or diabetes [12]. The
observed negative associations between excessive adi-
posity and HR-HPV infection were probable results of
vigilant screening or diagnosis. Furthermore, a cohort
effect could have also explained for an overall, low life-
time exposure risk for HPV in older women; [35] this
potential risk-modifying effect by age at sex debut was
particularly evident in the younger (aged 20–34) than
the older cohorts (aged 35–50 or 50–59).
To our knowledge, the current study was also among
the few investigations in examining metabolic health
effects on a specific infection. The finding that obese or
MUO (metabolically unhealthy obese) women showed a
significantly low probability for HR-HPV but not any-
type HPV infection has raised our concerns about a
biased, fasting subpopulation. Statistically, we have
accounted for the relative low participation of diabetic
participants in the fasting session by use of appropriate
sampling weights as suggested [22]. Fasting women
also appeared to have a similar degree of adiposity to
those in the primary analysis in terms of BMI, waist
circumference or WHtR (Additional file 1: Table S1).
The only apparent difference between the primary
and the fasting population was the highest degree of
educational attainment by study participants; 29.7 %
of fasting women reported a college education or
higher whereas 26.2 % of the overall analytic sample
did so (P = 0.041). We believe that selection bias was un-
likely to fully explain for the strong reverse associations
found between HR-HPV and metabolically unhealthy
obesity or obesity alone. Large longitudinal studies are
needed to prospectively assess influences of excessive
adiposity and its associated metabolic derangements on
the natural history of HPV infection.
Limitations
There are several limitations in interpreting our study
results. First, the lack of temporality was inherent in
the cross-sectional data. Cervical HPV infection is a
well-defined local infection, and the potential for
causing systemic ectopic disposition of fatty tissue is
thus unlikely. Nevertheless, the conjecture of infection-
associated adipogenesis needs to be prospectively evalu-
ated as in other obesity-inducing viral infections [36].
Secondly, the current study could not fully examine
whether or how the HPV immunization could have
affected the adiposity-HPV relationship. The documen-
tation of HPV vaccination among survey participants
began since 2006 and only a minority of women had
received the vaccine: 3.1 % in 2007–2008 and 5.2 %
in 2009–2010. When we repeated the analysis on
women enrolled in these two survey cycles (2007–2010,
N = 2568) and adjusted for the HPV vaccination history,
the strength of association between central obesity and
any-HPV was similar (aPR = 0.92) but was not statistically
significant (P = 0.171). Moreover, as we did not include
women of BMI < 18.5 Kg/m2 in the current analysis,
whether low adiposity correlated with a disproportionately
high likelihood for prevalent HPV (supporting a monoton-
ically deceasing, dose–response association); or whether
women of an abnormally low BMI they similarly exhibited
low rates of HPV infection (suggesting an inverse U-
shaped association) remains unexplored.
The current study also failed to examine for the con-
tribution of inflammatory proteins or cytokines to the
observed reverse associations because conventional in-
flammatory biomarkers, including ferritin or C-reactive
protein, were not available for women of all age groups
[21]. Among well-studied adipokines secreted by white
adipose tissues, leptin and adiponectin have been impli-
cated in changed immune responses by exerting their
pro- and anti-inflammatory activity in both innate and
adaptive immunity, separately [37, 38]. To elucidate the
mechanism involved in the polarization between pro- and
anti-inflammatory pathways during the development and
maintenance of visceral adiposity, longitudinally collected
immune correlates at the cervix may provide anchoring in-
formation to disentangle the causal from collateral events.
Lastly, according to Sumner and colleagues, the
currently-adopted, lipid-based definition for MetS were
likely to misclassify NHB women as metabolically healthy
when in fact they might already exhibit significant insulin
resistance [39]. Yet, ad-hoc sensitivity analysis that ex-
cluded NHB women from the fasting population revealed
unaltered results (data not shown). As such, we believed
that findings of the current study were at little risk for
ethnicity-associated misclassification bias.
Conclusions
In this US-representative adult female population,
obesity or central obesity was not substantially associ-
ated with HPV infection in general. However, in certain
subpopulations, women with excessive adiposity or its
relevant metabolic dysfunction showed a considerably
reduced HR-HPV prevalence. Particularly, early sex debut
in adolescence seemed to modulate such reduction in
obese or centrally-obese individuals. Prospective studies
are needed to further assess the influence of excessive adi-
posity on the natural course of HPV infection, particularly
on the initial acquisition and clearance in early adulthood
as well as on the viral persistence in later adulthood.
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